Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 10, 2025, under number D.25-0243.
This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene’s website (www.transgene.fr)
It includes the following documents:
- the Annual Financial Report;
- the Board of Directors’ Corporate Governance Report;
- the Statutory Auditors’ Reports;
- information on the Company’s share capital, including the share buyback program;
- information on the Statutory Auditors’ fees.
The Universal Registration Document also includes information on the Company’s Environmental, Social and Governance (ESG) factors.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer